[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574058":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":34,"collaborators":10,"id":36,"slug":10,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Experimental: 68Ga-NK224 PET\u002FCT",null,"Each participant receives a single intravenous injection of 68Ga-NK224, and undergo PET\u002FCT imaging within the specified time.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Liang Zhao","CONTACT","86 0592-213-7366","wzhaoliang01@163.com",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":27,"coordinates":28},"Point",[29,30],118.08187,24.47979,{"lat":30,"lon":29},[33],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100574058",false,"NCT06754345","68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);\n* (iii) patients who had scheduled 68Ga-NK224 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","90 Years",{"count":46,"type":47},100,"ESTIMATED","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the evaluation of PD-L1 expression in primary and\u002For metastatic tumors, compared with histopathological results.",[51,52],"Tumor","PD-L1",[51,52,54,55],"PET\u002FCT","diagnosis","2026-05-13",{"date":58,"type":59},"2026-05-15","ACTUAL",{"date":61,"type":59},"2023-05-30",{"date":63,"type":47},"2026-11-30",{"name":5,"class":6},1]